Moreover, blocking the other vital TAMs receptors (e.g., CSF-1R) and inhibitory receptors (e.g., LILRB1, LILRB2, CTLA-4) by nanobodies can improve the anti-tumor immunity in the TME through reprogramming of macrophages (145, 146). Here, CTLA4 is linked to neoplasm.